AIM ImmunoTech Inc. (AIMID)
OTCMKTS
· Delayed Price · Currency is USD
6.70
-1.68 (-20.05%)
At close: Jun 13, 2025
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $16.00K in the quarter ending March 31, 2025, a decrease of -60.00%. This brings the company's revenue in the last twelve months to $146.00K, down -24.35% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.
Revenue (ttm)
146.00K
Revenue Growth
-24.35%
P/S Ratio
40.83
Revenue / Employee
6.64K
Employees
23
Market Cap
5.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Federal National Mortgage Association | 30.44B |
Federal Home Loan Mortgage | 23.43B |
Jingbo Technology | 1.96M |
Alpine Auto Brokers | 129.78K |
First National of Nebraska | 1.89B |
Mechanics Bank | 381.61M |
Wilson Bank Holding Company | 189.72M |
Endo Inc. | 1.73B |
AIM ImmunoTech News
- 2 days ago - AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - GlobeNewsWire
- 2 days ago - AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewsWire
- 3 days ago - AIM ImmunoTech Announces 1-for-100 Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewsWire
- 2 months ago - NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire